Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia

• Status: Completed
• Trial end date: 2017-01-06
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to evaluate the rate of complete remission/complete remission with partial hematological recovery (CRh*) in adults with relapsed/refractory Philadelphia chromosome positive (Ph+) B-precursor acute lymphoblastic leukemia (ALL) who receive blinatumomab.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Treatments: Antibodies, Bispecific; Blinatumomab

Criteria

Inclusion Criteria

• Patients with Ph+ B-precursor ALL, with any of the following:

• Relapsed or refractory to at least one second generation tyrosine kinase inhibitor (TKI) (dasatinib, nilotinib, bosutinib, ponatinib)

• OR intolerant to second generation TKI and intolerant or refractory to imatinib mesylate

• Greater than 5% blasts in bone marrow

• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

• Age ≥ 18 years of age, at the time of informed consent.

• Subject has provided informed consent or subject's legally acceptable representative has provided informed consent when the subject has any kind of condition that, in the opinion of the Investigator, may compromise the ability of the subject to give written informed consent.

Exclusion Criteria

• History of malignancy other than ALL within 5 years prior to start of protocol-required therapy, except for adequately treated selected cancers without evidence of disease

• History or presence of clinically relevant central nervous system (CNS) pathology as epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis

• Active ALL in the CNS or testes

• Isolated extramedullary disease

• Current autoimmune disease or history of autoimmune disease with potential CNS involvement

• Allogeneic hematopoietic stem cell transplantation (HSCT) within 12 weeks before blinatumomab treatment

• Active acute or extensive chronic graft-versus-host disease (GvHD) which included the administration of immunosuppressive agents to prevent or treat GvHD within 2 weeks before blinatumomab treatment

• immediately previous cancer chemotherapy, radiotherapy, or immunotherapy; and eligibility for allogeneic HSCT at the time of enrollment.